Although doxorubicin interacts with DNA by intercalation inhibiting cancer cell growth, tamoxifen is a selective estrogen receptor modulator making them suitable for combination study due to their distinct mechanism of actions (Saueressig et al., 2018; Thorn et al., 2011; Vethakanraj & Kumar, 2017). The gene discussed is ESR1; the disease is cancer.